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In 2011, vaccination with a serogroup A meningococcal 
polysaccharide conjugate vaccine was implemented in 3 of 
23 regions in Chad. Cases of meningitis declined dramati-
cally in vaccinated areas, but an epidemic continued in the 
rest of Chad. In 2012, the remaining Chad population was 
vaccinated, and the epidemic was halted.
For >100 years, countries in the meningitis belt of Africa have experienced intermittent epidemics of meningo-
coccal meningitis, caused mainly by the serogroup A me-
ningococcus (1). After development and prequalification of 
a new serogroup A meningococcal polysaccharide/tetanus 
toxoid conjugate vaccine (PsA-TT) in 2009 (2), vaccina-
tion with PsA-TT across the meningitis belt commenced in 
2010, starting with persons 1–29 years of age in Burkina 
Faso and parts of Mali and Niger (3). Little transmission 
of the serogroup A meningococcus was occurring in these 
countries at the time of vaccine introduction, making evalu-
ation of its effectiveness difficult. 
In contrast, in Chad, PsA-TT was introduced in the 
middle of a serogroup A meningococcal epidemic, and 
vaccination with PsA-TT commenced at the end of 2011, 
shortly before the 2012 epidemic season. At this time, vac-
cination of persons 1–29 years of age (target 1.8 million) 
was undertaken in the capital N’Djamena, Mayo Kebbi Est, 
and Chari Baguirmi (4), designated here as the N’Djamena 
regions (Figure 1). In 2012, the vaccination program was 
extended to the rest of the country (target 5.9 million) (Fig-
ure 1). During the 2012 meningitis season, the incidence 
of meningitis decreased by >90% in vaccinated areas com-
pared with the rest of the country, and a similar reduction 
in the incidence of carriage of serogroup A Neisseria men-
ingitidis was found, as reported previously (4). We report 
on the incidence of meningitis during the 2013 meningitis 
season after vaccination of persons 1–29 years of age in 
areas with no prior vaccination program. 
The Study
In Chad, health districts provide aggregated weekly data 
on meningitis and other notifiable diseases to the Ministry 
of Health. This system was reinforced in 2012 and 2013 by 
case-based surveillance supported by the Centre du Sup-
port en Santé Internationale in the N’Djamena regions, and 
also by Médecins sans Frontières in Moissala, a district 
≈800 km from NDjamena (Figure 1). Cerebrospinal fluid 
(CSF) specimens obtained from persons with suspected 
cases of meningitis were transported to the national refer-
ence laboratory in NDjamena. Isolated strains of N. menin-
gitidis were sent to the World Health Organization (WHO) 
Intercountry Support Team, Ouagadougou, Burkina Faso, 
and to the WHO Collaborating Centre for Reference and 
Research on Meningococci in Oslo. Information about the 
laboratory methods used to isolate and characterize me-
ningococci is provided elsewhere (4). Data from the 2009 
census were used to calculate incidence rates. We used a 
negative binomial regression model to assess the effect of 
PsA-TT on the incidence of meningitis in the N’Djamena 
regions in 2012 and in the whole country in 2013; we used 
weekly data obtained during the epidemic period (weeks 
1–26) during 2009–2013.
The incidence of meningitis in Chad during 2009–
2013 and its association with the introduction of PsA-TT 
are shown in Figure 2. During weeks 1–26 of 2012, the 
incidence of reported meningitis among persons in all age 
groups in the N’Djamena regions that received vaccine was 
2.5 cases/100,000 population (57/2.3 million); during the 
previous year, incidence was 31.8/100,000 (732/2.3 mil-
lion). Meningitis incidence remained low in the N’Djamena 
regions in 2013 at 1.1/100,000 (25/2.3 million). In the rest 
of the country, in which vaccination was implemented 
during 2012 only, meningitis incidence decreased from 
43.8/100,000 (3,809/8.7 million) in weeks 1–26 of 2012 
to 2.8/100,000 (247/8.7 million) during the same period 
in 2013, a 96% reduction (p<0.0001). The incidence rate 
Continuing Effectiveness of Serogroup A  
Meningococcal Conjugate Vaccine, Chad, 2013
Author affiliations: Hôpital Général de Référence Nationale, 
N’Djamena, Chad (K. Gamougam); Centre de Support en Santé 
International, N’Djamena (D.M. Daugla, J. Toralta); Ministere de  
la Santé Publique, N’Djamena (C. Ngadoua); Epicentre–Médecins 
sans Frontières, Paris, France (F. Fermon, A.-L. Page); World 
Health Organization Intercountry Support Team, Ouagadougou, 
Burkina Faso (M.H. Djingarey); Norwegian Institute for Public 
Health, Oslo, Norway (D.A.Caugant); London School of Hygiene & 
Tropical Medicine, London, UK (O. Manigart, J.M. Stuart, B.M.  
Greenwood); and University of Cambridge, Cambridge, UK 
(C.L.Trotter)
DOI: http://dx.doi.org/10.3201/eid2101.140256
DISPATCHES
116 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 21, No. 1, January 2015
ratio for vaccinated versus unvaccinated populations was 
estimated by using data across the whole study period with 
a negative binomial regression model; the incidence rate 
ratio was 0.104 (95% CI 0.052–0.207).
Fewer CSF specimens were submitted to the national 
reference laboratory in N’Djamena in 2013 than in 2012 
(Table), but the proportion of reported cases for which CSF 
samples were submitted increased from 8.3% (273/3,308) 
in 2010, 7.9% (516/6,540) in 2011, and 9.5% (366/3,866) 
in 2012, to 39.3% (106/272) in 2013 (Pearson χ2 p<0.0001). 
The proportion of reported cases for which CSF samples 
were submitted from the N’Djamena regions was highest in 
2010, when the main pediatric unit for N’Djamena was in 
the same hospital as the national reference laboratory (the 
unit moved to another hospital in 2011) and in 2012, when 
case-based surveillance was introduced. In Moissala, the 
proportion of cases for which CSF samples were submitted 
increased from 22% (74/341) in 2012 to 119% (56/47) in 
2013, the latter figure being attributed to undernotification. 
During weeks 1–26 of 2013, a total of 106 CSF specimens 
were received by the national reference laboratory; 13 
yielded Streptococcus pneumoniae, 4 Haemophilus influ-
enzae type b, 2 N. meningitidis serogroup W, and 1 (ob-
tained from a 3-year-old child who had not received PsA-
TT) serogroup A N. meningitidis. Four infections were 
caused by other pathogens. This finding differed mark-
edly from those of previous years (2010-2012), when the 
predominant organism was N. meningitidis serogroup A, 
and only a few cases caused by N. meningitidis serogroup 
W and S. pneumoniae were also identified. The predomi-
nance of serogroup A infection in Chad during 2010–2012 
was confirmed among the CSF specimens examined at the 
National Institute of Public Health in Oslo. All fully char-
acterized serogroup A strains were porA 20.9, FetA F3.1, 
sequence type (ST) 7 (ST5 complex), and all serogroup W 
strains were porA 5.2, FetA F1–1, ST11 (ST11 complex). 
Although national reference laboratory data were not avail-
able in Chad for 2009, the predominant organism identified 
from CSF specimens received at the National Institute of 
Public Health in Oslo in 2009 was N. meningitidis sero-
group W (11/14 serogrouped strains), also porA 5.2, FetA 
F1–1, and ST11 (ST11 complex) (5).
Conclusions
We previously reported a >90% reduction in incidence of 
meningitis among vaccinated populations in Chad in 2011 
(4). Here we report a similar reduction in the incidence of 
meningitis in 2013 from that in 2012 for populations vac-
cinated only during the second year of the vaccination cam-
paign. The epidemic curve (Figure 2) suggests that by 2013, 
Figure 1. Areas of Chad in which 
vaccination with serogroup A 
meningococcal polysaccharide/
tetanus toxoid conjugate vaccine 
was implemented in 2011 (white) 
and 2012 (gray). Inset shows 
location of Chad in Africa.
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the N. meningitidis serogroup A epidemic in Chad was wan-
ing and that fewer cases of serogroup A meningitis would 
have occurred during 2013 than during 2012, even in the ab-
sence of vaccination. However, the incidence of meningitis 
dropped lower in 2013 than would have been expected as 
a result of a natural decline, and only 1 serogroup A iso-
late was obtained at the national reference laboratory despite 
improved CSF sampling. This finding provides strong ad-
ditional evidence of vaccine effectiveness for preventing se-
rogroup A meningococcal disease in Chad.
If the effectiveness of PsA-TT vaccination seen in 
Chad and Burkina Faso (6,7) is replicated across the menin-
gitis belt of Africa and if vaccine coverage can be sustained 
through introduction of PsA-TT into the infant immuniza-
tion program and/or through mass campaigns, serogroup 
A epidemics could disappear from the meningitis belt. 
However, past experience has shown that meningococci 
belonging to serogroups C, W, or X can cause substantial 
epidemics (8–10); therefore, continuing surveillance will 
be needed to determine how the epidemiology of meningo-
coccal disease in the meningitis belt of Africa is changed 
by the successful introduction of PsA-TT (11). The Chad 
Ministry of Health has approved a plan to support and de-
velop case-based surveillance in the N’Djamena regions, 
Moissala, and 3 other selected health districts.
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Figure 2. Incidence (no. 
cases/100,000 population) 
during weeks 1–26 of 
reported cases of meningitis 
in regions of Chad where 
persons 1–29 years of 
age were vaccinated with 
serogroup A meningococcal 
polysaccharide/tetanus 
toxoid conjugate vaccine at 
the end of 2011 and in 2012.
 
Table. Diagnoses of suspected meningitis cases from CSF specimens, Chad, weeks 1–26, 2010–2013* 
Location, year 
No. reports of 
suspected 
meningitis 
CSF specimens, 
no. (%) 
Diagnosis†  
N. meningitidis 
S. pneumoniae 
H. influenzae 
type b Other A W X Other 
N'Djamena regions          
 2010 268 158 (58.9) 27 2 0 2 8 0 0 
 2011 732 163 (22.3) 45 1 1 0 6 0 0 
 2012 57 37 (64.9) 0 0 2 0 0 0 0 
 2013 25 7 (28.0) 0 0 0 0 1 0 0 
Rest of Chad          
 2010 3,040 65 (2.1) 28 1 0 0 2 0 0 
 2011 5,808 353 (6.1) 110 1 1 0 0 1 0 
 2012 3,809 329 (8.6) 59 4 0 0 4 0 0 
 2013 247 99 (40.1) 1 2 0 0 12 4 4‡ 
*Diagnoses were based on cerebrospinal fluid (CSF) specimens received at the national reference laboratory in N’Djamena, Chad. Vaccination with 
serogroup A meningococcal polysaccharide/tetanus toxoid conjugate vaccine was implemented in the N’Djamena regions in 2011 and in all other regions 
of Chad in 2012. No reference laboratory data are available for 2009. N., Neisseria; S., Streptococcus; H., Haemophilus. 
†Based on culture or latex agglutination. 
‡Acinetobacter baumanii, Salmonella paratyphi A, Staphylococcus hominis, Staphylococcus aureus. 
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